Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents

Sharon Raimer, J. Michael Maloney, Marc Bourcier, David Wilson, Kim Papp, Elaine Siegfried, Steven Garrett

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Two 12-week, randomized, vehicle-controlled, double-blinded pivotal studies and a 12-month, long-term, open-label, noncomparative safety study were conducted to evaluate the efficacy and safety of dapsone gel 5% in patients with acne vulgaris. Of 3516 participants enrolled in the 3 trials, 1306 participants (37%) were adolescents aged 12 to 15 years and comprised the subgroup reported here. Participants randomly were assigned to twice-daily treatment with dapsone gel (n=578) or vehicle gel (n=547) in the pivotal studies and received open-label treatment with dapsone gel in the long-term safety study (n= 181). In the pivotal studies, success based on achieving a Global Acne Assessment Score (GAAS) of O (none) or 1 (minimal) at week 12 was significantly greater for the dapsone gel-treated adolescent participants (40.1%; 232/578) compared with the vehicle gel-treated adolescent participants (28.2%; 154/547)(P<.001). Treatment with dapsone gel in adolescents also resulted in clinically meaningful improvements in acne lesion counts by week 12 in the pivotal studies and for up to 12 months in the long-term safety study. The incidence of adverse events, including application-site events, was low and similar between treatment groups in the pivotal studies and was similarly low in the long-term safety study. Results from the large number of adolescent participants in these 3 studies show that dapsone gel is an effective and safe topical therapy for the treatment of acne vulgaris in adolescents aged 12 to 15 years for up to 12 months.

Original languageEnglish (US)
Pages (from-to)171-178
Number of pages8
JournalCutis
Volume81
Issue number2
StatePublished - Feb 2008

Fingerprint

Dapsone
Acne Vulgaris
Gels
Safety
Therapeutics
Incidence

ASJC Scopus subject areas

  • Dermatology
  • Immunology and Allergy

Cite this

Raimer, S., Maloney, J. M., Bourcier, M., Wilson, D., Papp, K., Siegfried, E., & Garrett, S. (2008). Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. Cutis, 81(2), 171-178.

Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. / Raimer, Sharon; Maloney, J. Michael; Bourcier, Marc; Wilson, David; Papp, Kim; Siegfried, Elaine; Garrett, Steven.

In: Cutis, Vol. 81, No. 2, 02.2008, p. 171-178.

Research output: Contribution to journalArticle

Raimer, S, Maloney, JM, Bourcier, M, Wilson, D, Papp, K, Siegfried, E & Garrett, S 2008, 'Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents', Cutis, vol. 81, no. 2, pp. 171-178.
Raimer S, Maloney JM, Bourcier M, Wilson D, Papp K, Siegfried E et al. Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. Cutis. 2008 Feb;81(2):171-178.
Raimer, Sharon ; Maloney, J. Michael ; Bourcier, Marc ; Wilson, David ; Papp, Kim ; Siegfried, Elaine ; Garrett, Steven. / Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. In: Cutis. 2008 ; Vol. 81, No. 2. pp. 171-178.
@article{8aa58d8cd947410f9b3923703356e4f1,
title = "Efficacy and safety of dapsone gel 5{\%} for the treatment of acne vulgaris in adolescents",
abstract = "Two 12-week, randomized, vehicle-controlled, double-blinded pivotal studies and a 12-month, long-term, open-label, noncomparative safety study were conducted to evaluate the efficacy and safety of dapsone gel 5{\%} in patients with acne vulgaris. Of 3516 participants enrolled in the 3 trials, 1306 participants (37{\%}) were adolescents aged 12 to 15 years and comprised the subgroup reported here. Participants randomly were assigned to twice-daily treatment with dapsone gel (n=578) or vehicle gel (n=547) in the pivotal studies and received open-label treatment with dapsone gel in the long-term safety study (n= 181). In the pivotal studies, success based on achieving a Global Acne Assessment Score (GAAS) of O (none) or 1 (minimal) at week 12 was significantly greater for the dapsone gel-treated adolescent participants (40.1{\%}; 232/578) compared with the vehicle gel-treated adolescent participants (28.2{\%}; 154/547)(P<.001). Treatment with dapsone gel in adolescents also resulted in clinically meaningful improvements in acne lesion counts by week 12 in the pivotal studies and for up to 12 months in the long-term safety study. The incidence of adverse events, including application-site events, was low and similar between treatment groups in the pivotal studies and was similarly low in the long-term safety study. Results from the large number of adolescent participants in these 3 studies show that dapsone gel is an effective and safe topical therapy for the treatment of acne vulgaris in adolescents aged 12 to 15 years for up to 12 months.",
author = "Sharon Raimer and Maloney, {J. Michael} and Marc Bourcier and David Wilson and Kim Papp and Elaine Siegfried and Steven Garrett",
year = "2008",
month = "2",
language = "English (US)",
volume = "81",
pages = "171--178",
journal = "Cutis",
issn = "0011-4162",
publisher = "Quadrant Healthcom Inc.",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents

AU - Raimer, Sharon

AU - Maloney, J. Michael

AU - Bourcier, Marc

AU - Wilson, David

AU - Papp, Kim

AU - Siegfried, Elaine

AU - Garrett, Steven

PY - 2008/2

Y1 - 2008/2

N2 - Two 12-week, randomized, vehicle-controlled, double-blinded pivotal studies and a 12-month, long-term, open-label, noncomparative safety study were conducted to evaluate the efficacy and safety of dapsone gel 5% in patients with acne vulgaris. Of 3516 participants enrolled in the 3 trials, 1306 participants (37%) were adolescents aged 12 to 15 years and comprised the subgroup reported here. Participants randomly were assigned to twice-daily treatment with dapsone gel (n=578) or vehicle gel (n=547) in the pivotal studies and received open-label treatment with dapsone gel in the long-term safety study (n= 181). In the pivotal studies, success based on achieving a Global Acne Assessment Score (GAAS) of O (none) or 1 (minimal) at week 12 was significantly greater for the dapsone gel-treated adolescent participants (40.1%; 232/578) compared with the vehicle gel-treated adolescent participants (28.2%; 154/547)(P<.001). Treatment with dapsone gel in adolescents also resulted in clinically meaningful improvements in acne lesion counts by week 12 in the pivotal studies and for up to 12 months in the long-term safety study. The incidence of adverse events, including application-site events, was low and similar between treatment groups in the pivotal studies and was similarly low in the long-term safety study. Results from the large number of adolescent participants in these 3 studies show that dapsone gel is an effective and safe topical therapy for the treatment of acne vulgaris in adolescents aged 12 to 15 years for up to 12 months.

AB - Two 12-week, randomized, vehicle-controlled, double-blinded pivotal studies and a 12-month, long-term, open-label, noncomparative safety study were conducted to evaluate the efficacy and safety of dapsone gel 5% in patients with acne vulgaris. Of 3516 participants enrolled in the 3 trials, 1306 participants (37%) were adolescents aged 12 to 15 years and comprised the subgroup reported here. Participants randomly were assigned to twice-daily treatment with dapsone gel (n=578) or vehicle gel (n=547) in the pivotal studies and received open-label treatment with dapsone gel in the long-term safety study (n= 181). In the pivotal studies, success based on achieving a Global Acne Assessment Score (GAAS) of O (none) or 1 (minimal) at week 12 was significantly greater for the dapsone gel-treated adolescent participants (40.1%; 232/578) compared with the vehicle gel-treated adolescent participants (28.2%; 154/547)(P<.001). Treatment with dapsone gel in adolescents also resulted in clinically meaningful improvements in acne lesion counts by week 12 in the pivotal studies and for up to 12 months in the long-term safety study. The incidence of adverse events, including application-site events, was low and similar between treatment groups in the pivotal studies and was similarly low in the long-term safety study. Results from the large number of adolescent participants in these 3 studies show that dapsone gel is an effective and safe topical therapy for the treatment of acne vulgaris in adolescents aged 12 to 15 years for up to 12 months.

UR - http://www.scopus.com/inward/record.url?scp=41149092945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149092945&partnerID=8YFLogxK

M3 - Article

C2 - 18441772

AN - SCOPUS:41149092945

VL - 81

SP - 171

EP - 178

JO - Cutis

JF - Cutis

SN - 0011-4162

IS - 2

ER -